Ocugen Completes Dosing for Stargardt Disease Trial

Ocugen has announced the early completion of patient dosing for its Phase 2/3 GARDian3 pivotal confirmatory trial of OCU410ST, a treatment for Stargardt disease. The trial enrolled 63 participants and concluded dosing in under nine months. Topline results are anticipated in the second quarter of 2027, with a Biologics License Application (BLA) submission expected by mid-2027. This milestone represents significant progress in the development of a potential therapy for this rare inherited retinal condition, bringing hope to patients and families affected by Stargardt disease.